Contract development and manufacturing organizations (CDMOs) are the foundation of the modern peptide supply chain. The GLP-1 wave overwhelmed legacy SPPS capacity through 2023-2025, and the 2026 CDMO sector is in the middle of its largest capacity buildout in two decades — Bachem (Bubendorf, Vista, Sisslerfeld, St Helens), PolyPeptide (Malmö, Braine-l'Alleud, San Diego), CordenPharma ($200M+ Swiss greenfield plus the AmbioPharm acquisition adding US and Shanghai sites), and a growing tier of Asian CDMO entrants.
The sector is also consolidating along specialty lines. The Indena + Chemi S.p.A. (Italfarmaco) June 2026 partnership pairs peptide chemistry with high-potency API conjugation for the peptide-drug-conjugate modality — one of several deals that reflect how CDMOs are pairing complementary capabilities rather than building everything in-house. The pattern matches CordenPharma's AmbioPharm acquisition, the Bachem strategic-asset April 2026 deal, and Lonza's continued SPPS capacity additions.
The regulatory backdrop tightened in 2026. The EMA's first-ever synthetic peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025) took effect June 1, 2026, codifying manufacturing-route and impurity expectations across human and veterinary peptide APIs. Stories here cover capacity expansions, contract wins, M&A, leadership transitions, and the broader manufacturing economy that determines what the next wave of peptide drugs can be supplied at scale. See [[bachem]], [[polypeptide]], [[cordenpharma]], [[peptide-manufacturing]], and [[manufacturing]] for adjacent threads.
Indena and Chemi S.p.A. (Italfarmaco Group) announced a strategic partnership in June 2026 combining peptide chemistry and high-potency API (HPAPI) conjugation expertise to position both firms as development and manufacturing partners for biotech and pharmaceutical companies pursuing peptide-drug conjugates (PDCs). Under the agreement, Chemi supplies the peptide carrier molecules and Indena handles the conjugation with highly potent payload molecules. Neither company is developing proprietary PDC drugs; the partnership reflects the broader CDMO consolidation pattern as the PDC modality scales (six PDCs in Phase 3 trials and ~96 in development globally per the April 2026 ResearchAndMarkets report, with Lutathera as the only FDA-approved standalone PDC after Pepaxto's withdrawal and the Pepaxti EMA expansion application pending). The partnership lands alongside CordenPharma's AmbioPharm acquisition and the broader sector reshaping.
Catalent's TIDES USA 2026 presence centers on oral macromolecule delivery — the bottleneck that has kept all but a handful of peptides off the oral-route market. The contract development and manufacturing organization is showcasing its Zydis fast-dispersion platform, ZipDose 3D-printed dose-form technology, and oral macromolecule delivery systems engineered for peptides and proteins up to ~100,000 Da. The portfolio targets the post-orforglipron oral-GLP-1 reference architecture: SNAC permeation enhancers (Novo Nordisk's oral semaglutide approach), lipidation chemistry, and protective formulation matrices. Catalent's positioning aligns with the broader CDMO build-out — PolyPeptide's May EUR 200M credit facility, CordenPharma's $500M Boulder SPPS expansion — converging on Boston this week.
Swiss peptide CDMO Bachem announced a strategic partnership and asset acquisition in April 2026 to scale large-scale peptide API production. The move responds to surging demand for GLP-1 and next-generation peptide drugs — the global peptide synthesis market is now projected to reach $2.26 billion by 2033 at an 11.4% CAGR. Bachem previously secured a CHF 1 billion peptide supply contract and is operating three site expansions to address capacity constraints that have periodically disrupted semaglutide and tirzepatide supply.